At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 252 enrolled
Drug / intervention
Romosozumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
In Brief
A Phase 2 clinical trial evaluating Romosozumab and Placebo for Postmenopausal Osteoporosis (PMO). Completed, enrolled 252 participants across 27 sites.
Detailed Summary
The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis (PMO)
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedNov 2013
Primary CompletionOct 2014
Study CompletionJun 2015
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartOct 12, 2012
Primary CompletionOct 9, 2014
Study CompletionJun 17, 2015
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.6 years ago
Interventions
Romosozumabdrug
Administered by subcutaneous injection
Placebodrug
Administered by subcutaneous injection